Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services has informed stock exchanges that its subsidiary, Optival Health Solutions Private Limited, received two drug license suspension orders from Drug Control Administration authorities. The first order, from Bangalore Circle-Bidar in Karnataka, suspends the drug license of the Bidar (old city fort area) store for two days, with a potential revenue loss of around Rs 0.50 lakhs. The second order, from Hyderabad in Telangana, suspends the drug license of the Priya Colony Gudimalkapur store for two days, with a potential revenue loss of around Rs 0.68 lakhs. Both suspensions were issued under Rule 65 of the Drugs and Cosmetics Act, 1940, and the orders were received on May 15, 2025. The total combined potential revenue impact is approximately Rs 1.18 lakhs.
The financial impact is negligible (around Rs 1.18 lakhs combined) given Medplus operates thousands of stores, so this is unlikely to materially affect the stock price. However, it signals routine regulatory scrutiny on pharma retail operations.